AEON Biopharma Statistics
Total Valuation
AEON Biopharma has a market cap or net worth of $88.81 million. The enterprise value is $83.65 million.
Market Cap | 88.81M |
Enterprise Value | 83.65M |
Important Dates
The next estimated earnings date is Monday, August 12, 2024, before market open.
Earnings Date | Aug 12, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
AEON Biopharma has 39.12 million shares outstanding. The number of shares has decreased by -73.24% in one year.
Shares Outstanding | 39.12M |
Shares Change (YoY) | -73.24% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 40.15% |
Owned by Institutions (%) | 24.30% |
Float | 16.07M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.48
Current Ratio | 0.48 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -3,676.50% |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | -$32.40M |
Employee Count | 10 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.40% in the last 52 weeks. The beta is 0.40, so AEON Biopharma's price volatility has been lower than the market average.
Beta (5Y) | 0.40 |
52-Week Price Change | -73.40% |
50-Day Moving Average | 1.52 |
200-Day Moving Average | 5.95 |
Relative Strength Index (RSI) | 60.56 |
Average Volume (20 Days) | 4,963,475 |
Short Selling Information
The latest short interest is 145,892, so 0.37% of the outstanding shares have been sold short.
Short Interest | 145,892 |
Short Previous Month | 180,364 |
Short % of Shares Out | 0.37% |
Short % of Float | 0.91% |
Short Ratio (days to cover) | 2.11 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -371.19M |
Pretax Income | -323.95M |
Net Income | -323.95M |
EBITDA | -323.91M |
EBIT | -323.95M |
Earnings Per Share (EPS) | -$8.72 |
Balance Sheet
The company has $5.16 million in cash and no debt, giving a net cash position of $5.16 million or $0.13 per share.
Cash & Cash Equivalents | 5.16M |
Total Debt | n/a |
Net Cash | 5.16M |
Net Cash Per Share | $0.13 |
Equity (Book Value) | -153.04M |
Book Value Per Share | -3.91 |
Working Capital | -6.83M |
Cash Flow
Operating Cash Flow | -26.08M |
Capital Expenditures | n/a |
Free Cash Flow | -26.08M |
FCF Per Share | -$0.70 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
AEON Biopharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 73.24% |
Shareholder Yield | 73.24% |
Earnings Yield | -364.78% |
FCF Yield | -29.37% |
Analyst Forecast
The average price target for AEON Biopharma is $6.00, which is 166.67% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $6.00 |
Price Target Difference | 166.67% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 3 |